Preclinical Efficacy And Safety Evaluation Of Graphene Nanoparticle-based Magneti

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$415,078.00
Award Year:
2013
Program:
SBIR
Phase:
Phase I
Contract:
1R43DK098959-01A1
Agency Tracking Number:
R43DK098959
Solicitation Year:
2013
Solicitation Topic Code:
NIDDK
Solicitation Number:
PA13-088
Small Business Information
NOVATARG, INC.
R DAVID THOMAS CENTER, BOX 90344, DURHAM, NC, 27708-
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
962942863
Principal Investigator:
KEN BATCHELOR
(919) 354-1066
kwb10@duke.edu
Business Contact:
KENNETH BATCHELOR
(919) 406-4367
kwb10@duke.edu
Research Institution:
Stub




Abstract
DESCRIPTION (provided by applicant): There are approximately 12 million people suffering from autosomal dominant polycystic kidney disease (ADPKD) worldwide. ADPKD is a chronic condition with no effective drug therapies available; dialysis and transplantation are performed at costs of gt 2 billion/year in the US. NovaTarg has developed a novel and kidney selective approach to PKD treatment which is expected to generate drugs that block underlying disease processes and to provide innovative therapies for PKDpatients. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: There are approximately 12 million people suffering from autosomal dominant polycystic kidney disease (ADPKD) worldwide. ADPKD is a chronic condition with no effective drug therapies available; dialysis and transplantation are performed at costs of gt 2 billion/year in the US. NovaTarg has developed a novel and kidney selective approach to PKD treatment which is expected to generate drugs that block underlying disease processes and to provide innovative therapies for PKD patients.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government